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INTRODUCTION
The prevalence of drug hypersensitivity reactions is increas-
ing. Detection of the culprit drug is a prerequisite for effective 
prevention by substituting safer alternatives. Aspirin and non-
steroidal anti-inflammatory drugs (ASA/NSAIDs) are among 
the most common causes of hypersensitivity reactions, account-
ing for 0.6%-2.5% of hypersensitivity reactions in the general 
population and 10%-20% in asthmatic patients.
1,2 A previous 
study at a tertiary care hospital in Korea reported that ASA/
NSAIDs ranked first among the drugs provoking hypersensitiv-
ity reactions.
3 Nevertheless, a definitive diagnosis of ASA/NSAID-
induced hypersensitivity is difficult because these are usually 
administered in combination with other drugs, making it nec-
essary to test all drugs taken. Although hypersensitivity reactions 
to some drugs can be detected by topical provocation tests, re-
actions to ASA/NSAIDs, except for aspirin-induced asthma, 
can be detected only by an oral provocation test. However, oral 
provocation tests are contraindicated in subjects who have ex-
perienced severe reactions such as anaphylactic shock,
4 and 
many subjects who have experienced drug hypersensitivity re-
actions are not willing to risk an oral provocation test.
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Numerous methods have been proposed to diagnose ASA/
NSAIDs hypersensitivity. In vivo methods include the skin prick 
test (SPT),
5 the autologous serum skin test,
6,7 and measurement 
of urine leukotriene E4 before and after ingestion of the sus-
pected drug.
8 In vitro, analysis of genetic polymorphisms relat-
ed to metabolism of arachidonic acid,
9,10 measurement of 15-
HETE in the reaction between ASA/NSAIDs and leukocytes,
11 
and the cellular allergen stimulation test (CAST) using baso-
phils
12,13 have been investigated.
Here, we used a flow cytometry-assisted basophil activation 
test (FAST) to analyze CD63 exposure upon basophil degranu-
lation. CD63 is anchored in the basophilic granular membrane 
and can be detected on the outside of the cell upon the fusion 
of granules with plasma membranes.
14 FAST has high sensitivi-
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Purpose:  Aspirin and non-steroidal anti-inflammatory drugs (ASA/NSAIDs) are common causes of drug hypersensitivity. An oral provocation test is 
the only definitive diagnostic test. This study assessed the reliability of a flow cytometry-assisted basophil activation test (FAST) as a safe diagnostic 
method for ASA/NSAID-induced hypersensitivity, as its high sensitivity and specificity have been demonstrated for many other drugs.  Methods:  Eigh-
teen patients and 11 controls were enrolled. Using a Flow-CAST kit
® (Bühlmann Laboratories AG, Schönenbuch, Switzerland), 29 analyses with as-
pirin, ibuprofen, and diclofenac were performed by flow cytometry to detect double-positive staining of anti-IgE and anti-CD63. The stimulation in-
dex was defined as the activated basophil percentage after drug stimulation/basally active basophil percentage. A stimulation index≥2 and an ab-
solute activated basophil percentage≥5 were considered positive.  Results:  Patients with hypersensitivity to ASA/NSAIDs were predominantly 
female, and the prevalence of atopy was higher in patients than in controls. A sensitivity of 61%, specificity of 91%, positive predictive value of 
92%, and negative predictive value of 59% were achieved.  Conclusions:  FAST is a useful additional method for diagnosis of hypersensitivity re-
actions to ASA/NSAIDs. Further development is required to increase the sensitivity of the test.
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ty and specificity for the diagnosis of hypersensitivity reactions 
to inhalant allergens, bee venom, and latex.
15 Some studies on 
hypersensitivity to ASA/NSAIDs have found high specificity of 
FAST,
18-20 but reported sensitivities vary.
The present study was conducted to corroborate the applica-
bility of FAST for detecting hypersensitivity to ASA/NSAIDs and 
to evaluate its efficacy in Koreans by determining its sensitivity, 
specificity, and positive/negative predictive values.
MATERIALS AND METHODS
Study subjects
This study included 18 patients who showed hypersensitivity 
reactions to ASA/NSAIDs at our allergy clinic between August 
2007 and August 2008. Skin reactions were provoked in 13 sub-
jects; respiratory reactions, in two; and anaphylactic shock, in 
three. The control group comprised 11 subjects who were 
matched for age and gender (ratio, 2:1) with the study group. 
The control subjects were patients admitted with other diseases 
(n=5) or were healthy subjects (n=3). Three subjects who 
showed hypersensitivity reactions to drugs other than ASA/
NSAIDs were also included as controls. We confirmed that the 
control subjects had experienced no hypersensitivity reactions 
to ASA/NSAIDs. All subjects were informed orally about the 
study and provided informed consent. The study was approved 
by the local institutional review board.
Clinical features, including the types of drugs producing hy-
persensitivity reactions, time interval from drug ingestion to 
symptom onset, and types of hypersensitivity reactions, as well 
as past histories of bronchial asthma, allergic rhinitis, food al-
lergy, and chronic urticaria, were collected for each subject. Se-
rum total IgE was measured, and specific IgE was determined 
using the multiple allergen simultaneous test (MAST). SPTs 
were performed for common inhalant and food allergens, and 
atopy was defined as a positive SPT result.
Sample analysis
Blood samples were drawn from the subjects at least 2 weeks 
after hypersensitivity reactions and also at least 1 week after 
discontinuation of anti-allergic medications such as antihista-
mines, antileukotrienes, and steroids. The cells were stimulated 
within 2 hours after blood sampling, or the samples were im-
mediately refrigerated for up to 24 hours. Experiments were 
performed using a commercially available Flow-CAST kit
® 
(Bühlmann Laboratories AG, Schönenbuch, Switzerland) fol-
lowing the manufacturer’s instructions, as has been fully de-
scribed and discussed elsewhere.
14-23
For analysis, blood was collected in an EDTA tube and centri-
fuged for 5 minutes at 1,100 rpm. The leukocyte-containing 
plasma fraction was then centrifuged for 10 minutes at 1,700 
rpm to obtain a leukocyte pellet, which was carefully resuspend-
ed with 100 μL of stimulation buffer per 1 mL of original blood 
sample. Each patient’s cell suspension was divided among five 
test tubes (50 μL per tube). Stimulation buffer was added to one 
tube as a negative control; anti-IgE receptor antibody was add-
ed to another tube as a positive control. To the remaining three 
tubes, 50 μL of aspirin (1.25 mg/mL), ibuprofen (50 μg/mL), or 
diclofenac (12.5 μg/mL) were added. The tubes were vortexed 
gently and incubated at 37°C for 40 minutes. The reaction was 
halted by adding 50 μL of pre-cooled blocking buffer to each 
tube. Leukocytes were labeled using FITC-conjugated anti-IgE 
and PE-conjugated anti-CD 63.
The samples were analyzed using CellQuest
® containing 488-
nm argon within 2 hours. The cutoff points for anti-IgE-FITC 
and anti-CD63-PE were determined for each subject based on 
the point where the initial fluorescence peak was observed in 
the positive control (Fig. 1). The percentage of basophils posi-
tive for both IgE and CD 63 was obtained. The stimulation in-
dex (SI) was calculated using the following formula:
SI=percentage of basophils activated by the drug/percentage of 
activated basophils in the negative control
The receiver operating characteristics (ROC) curve was used 
to determine a cutoff point for the SI. A positive result was de-
fined as a SI≥2 (Fig. 2), which was similar to previous stud-
ies.
18-21,23 To account for nonspecific activation, only activated 
basophil percentages≥5% were considered positive.
Statistical analysis 
Statistical analysis was performed using SPSS ver. 16.0 (SPSS 
Inc., Chicago, IL, USA). As the number of subjects was small, 
continuous variables were analyzed using the Mann-Whitey U 
test, and categorical variables were analyzed using Fisher’s ex-
act test. A P value<0.05 was considered to indicate significance. 
The FAST results are expressed as the percentage of basophils 
positive for both IgE and CD63.
RESULTS
Demographic and clinical characteristics of the study and 
control groups
Table 1 presents the demographic and clinical characteristics 
of the study and control groups. The ratio of males to females in 
the study group was 1:3.5, and the prevalence of atopy was sig-
nificantly higher in the study group than in control group (61% 
vs. 36%; P<0.05). Eight of the 18 study subjects (44%) had pre-
viously experienced hypersensitivity reactions to ASA/NSAIDs. 
Of these eight, one had also experienced hypersensitivity to a 
drug other than ASA/NSAIDs (an iron preparation). In the con-
trol group, two subjects had a history of hypersensitivity to pen-
icillin; and one, to cimetidine. Culprit drugs for the current re-
actions in the study group were aspirin (n=6), propionic acid 
derivatives (ibuprofen, naproxen; n=8), acetic acid derivatives Basophil Activation Test in Aspirin Sensitivity
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(diclofenac, aceclofenac; n=2), piroxicam (n=1), and Joins
® 
(Clematis mandshurica, Trichosanthes kirilowii, Prunella vul-
garis; n=1).
Flow cytometry-assisted basophil activation test
The FAST results are shown in Tables 2 and 3. There was no 
significant difference in the mean FAST result for the negative 
test control (3.26%±1.68% vs. 2.25%±1.93%) or positive test 
Table 1.  Demographic features and clinical characteristics
Characteristic Study group Control group
Age, yr (mean±SD) 33±14 34±13
Gender, M:F 4:14 (22:78) 4:7 (36:64)
Atopy status* 11 (61) 4 (36)
History of drug allergy
None* 9 (50) 8 (73)
ASA/NSAIDs* 8 (44) 0
Other drugs 2 (11) 3 (27)
Culprit drugs
Salicylates (Aspirin, isopropylantipyrine) 6 (33) None
Propionic acids (Ibuprofen, naproxen) 8 (44)
Acetic acids (Diclofenac) 2 (11)
Other NSAIDs
† 2 (11)
Type of hypersensitivity
Respiratory 2 (11) None
Cutaneous 13 (72)
Anaphylaxis 3 (17)
Values are given as number (%), unless otherwise indicated.
NSAIDs, non-steroidal anti-inflammatory drugs.
*P<0.05.
†Other NSAIDs include piroxicam and Joins
®.
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Fig. 1.  Representative aspirin hypersensitivity results. (A) The cutoff point 
(arrow) for anti-CD63-PE was established according to the initiation of a flu-
orescence peak in the positive control. Shaded histogram, negative control 
(stimulation buffer); solid gray lines, positive control (anti-FcεRI antibody). (B) 
A sample stimulated with aspirin showing activation of 25.69% of baso-
phils. (C) A sample stimulated with ibuprofen showing activation of 2.11% 
of basophils. (D) A sample stimulated with diclofenac showing activation of 
4.57% of basophils. The SI of aspirin was >2, indicating a positive result. 
The percentage of activated basophils was low (<5%) upon stimulation 
with ibuprofen or diclofenac, indicating a negative result for each.
control (73.73%±19.78% vs. 63.91%±26.03%) between the 
study and control groups. The FAST results showed a specificity 
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Fig. 2.  The receiver operating characteristics (ROC) curve. According to the 
ROC curve, the optimal cutoff point for the stimulation index was 1.9 (arrow). 
The observed area under the curve was 0.72 (95% Confidence Interval, 0.53-
0.93; P=0.039), which is considered fair.Kim et al.
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of 91%, positive predictability of 92%, sensitivity of 61%, and 
negative predictability of 59%.
For patients with hypersensitivity reactions to salicylate, the 
FAST results for aspirin were positive in 50%. All patients who 
showed hypersensitivity to propionic derivatives and acetic 
acid derivatives showed a negative response to ibuprofen and 
diclofenac, respectively.
Within the study group, atopy status did not affect the FAST 
results. The FAST results did not differ significantly between 
study subjects with cutaneous symptoms and those with respi-
ratory symptoms, or between those with mild symptoms and 
those with severe symptoms (Table 4).
DISCUSSION
The aim of the present study was to evaluate the efficacy of 
FAST for the diagnosis of hypersensitivity to ASA/NSAIDs. There 
are many reports in the European literature regarding the use of 
Table 2.  FAST results in study subjects with aspirin/ibuprofen/diclofenac hypersensitivity
Study  
subject
Reaction Gender/Age Culprit drug
% Activated basophils in FAST (SI)
Control value Test drug value
(-) (+) ASA IBU DIC
1 Asthma F/37 ASA 4.75 18.79 7.72 (1.63)
2 Urticaria F/43 ASA 4.68 74.38 4.19 (0.90)
3 Angioedema F/26 IBU 0.69 47.12 1.78 (2.58) 1.95 (2.83) 2.58 (3.74)
4 Angioedema F/22 NPX 1.13 46.65 5.28 (4.67)* 0.46 (0.41) 3.41 (3.02)
5 Anaphylactic shock F/24 ASA 4.49 41.27 1.72 (0.38) 1.05 (0.23) 0.73 (0.16)
6 Angioedema M/15 IBU 1.43 77.65 10.00 (6.99)* 2.94 (2.06) 0 (0)
7 Angioedema M/16 IBU 4.71 75.40 11.33 (2.41)* 4.92 (1.04) 9.29 (1.97)
8 Angioedema M/31 PRX 2.33 77.73 11.09 (4.76)* 0.29 (0.12)
9 Angioedema F/30 IBU 4.08 87.15 15.09 (3.70)*
10 Angioedema  F/36 NPX 2.33 88.24 0.39 (0.17)
11 Angioedema  F/18 NPX 0.83 82.76 25.69 (30.95)* 2.11 (2.54) 4.57 (5.51)
12 Angioedema  F/26 IPA 2.44 84.30 7.49 (3.07)* 1.67 (0.68) 2.28 (0.93)
13 Asthma  F/66 ASA 6.49 89.02 13.30 (2.05)* 4.56 (0.70) 18.77 (2.89)*
14 Anaphylactic shock F/46 Joins
® 1.68 85.43 2.95 (1.76) 1.86 (1.11) 1.56 (0.93)
15 Anaphylactic shock F/43 DIC 2.41 92.25 8.11 (3.37)* 1.24 (0.51) 1.05 (0.44)
16 Angioedema M/49 IBU 4.59 90.45 8.35 (1.82) 1.58 (0.34) 5.43 (1.18)
17 Angioedema F/36 ASA 4.85 84.35 17.84 (3.68)* 4.13 (0.85) 2.85 (0.59)
18 Angioedema  F/31 DIC 4.81 84.25 13.04 (2.71)*
SI, stimulation index; ASA, aspirin; IBU, ibuprofen; DIC, diclofenac; IPA, isopropylantipyrine; NPX, naproxen; PRX, piroxicam.
Positive results are indicated by* (% activated basophils≥5% and SI≥2).
Table 3.  FAST results in the control group
Control 
subject
Gender/
Age
% Activated basophils in FAST (SI)
Control value Test drug value
(-) (+) ASA IBU DIC
1 F/29 5.07 87.50 6.41 (1.26)
2 M/16 4.37 25.94 2.79 (0.64) 1.47 (0.34) 1.59 (0.36)
3 M/22 0.32 72.37 1.57 (4.91)
4 M/43 2.19 66.92 3.71 (1.69) 1.84 (0.84) 3.06 (1.40)
5 F/18 4.61 49.62 8.45 (1.83) 3.49 (0.76) 3.82 (0.83)
6 F/57 4.17 91.43 5.56 (1.33)
7 F/29 1.32 64.85 4.53 (3.43)
8 F/32 1.02 93.47 10.92 (10.71)*
9 F/34 0.54 62.04 2.78 (5.15)
10 F/43 1.11 76.87 1.92 (1.73)
11 F/48 0.10 12.05 3.64 (36.40)
FAST, flow cytometry-assisted basophil activation test; SI, stimulation index; 
ASA, aspirin; IBU, ibuprofen; DIC, diclofenac.
Positive results are indicated by* (% activated basophils≥5% and SI≥2).
Table 4.  Comparison of FAST results according to the type of aspirin/ibupro-
fen/diclofenac hypersensitivity
Type of NSAID hypersensitivity Positive results in FAST
Respiratory  1/2 (50)
Cutaneous  9/13 (69)
Anaphylactic shock 1/3 (33)
Values are given as No. (%).
FAST, flow cytometry-assisted basophil activation test; NSAID, non-steroidal 
anti-inflammatory drug.Basophil Activation Test in Aspirin Sensitivity
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FAST to test reactivity to ASA/NSAIDs,
18-21 diclofenac,
22 or met-
amizol.
23 These studies applied a SI≥2 as a cutoff on the basis 
of high specificity under the ROC curve, because the prevalence 
of hypersensitivity reactions to ASA/NSAIDs was relatively low. 
Although the specificity and positive predictive value were re-
ported to be 100% in all of these previous studies, the sensitivity 
varied between 40% and 70%.
18-23
In the present study using a SI cutoff of 2, FAST showed a 
specificity of 91%, positive predictive value of 92%, sensitivity of 
61%, and negative predictive value of 59%. The SI cutoff point, 
sensitivity, and specificity were similar to those in previous 
studies.
18-23 Neither atopy status nor the type and severity of hy-
persensitivity reactions affected the FAST results, which was 
also similar to previous results.
18,21
Two earlier studies demonstrated that 27%-66% of subjects 
with hypersensitivity to one ASA/NSAID showed a positive 
FAST result with other ASA/NSAIDs. However, similar results 
were not obtained in the present study, probably owing to the 
small sample size.
In the present study, the specificity was relatively low, and all 
subjects showed positive FAST results only for aspirin, regard-
less of the culprit drug. The control subject who showed a posi-
tive FAST result had a negative oral aspirin provocation test re-
sult. The discrepancy between the results of previous European 
studies and ours may be explained by differences in race and/
or drug concentration.
We employed commercially available concentrations of drugs 
based on the dose-reaction relationship. The concentrations of 
aspirin used in this study were similar to those used in previous 
studies, and the sensitivity and specificity were also similar. Pre-
vious studies tested with 1-100 μg/mL of ibuprofen and 1-310 
μg/mL of diclofenac, and one study reported a sensitivity of 
29% for ibuprofen and 50% for diclofenac at concentrations 
lower than those used here.
21 The maximum blood concentra-
tions in vivo after ingestion of the medications were 15-55 and 
0.5-2.5 μg/mL for ibuprofen and diclofenac, respectively.
25 
These values are lower than those obtained in our study. One 
report concluded that the use of higher drug concentrations 
appeared to increase the sensitivity of FAST because the high 
drug doses induced nonspecific basophil activation.
26 We infer 
that in the present study, the drug concentrations did not affect 
the FAST results.
The low sensitivity of 65% for ASA/NSAID-induced hypersen-
sitivity may be a drawback of FAST. Two studies from the U.S. 
and Turkey showed negative FAST results.
26,27 The U.S. study re-
ported sensitivities of 30% for aspirin at 0.3-1.25 mg/mL and 
80% at 5 mg/mL; however, high aspirin concentrations also 
stimulated basophils in the control group, indicating poor spec-
ificity.
26 The Turkish study found very low sensitivity (16.7%-
33.3%).
27 The low sensitivities may be attributable to the fact 
that mast cells and eosinophils are also involved in hypersensi-
tivity reactions to ASA/NSAIDs. There is no direct evidence for 
the involvement of basophils in ASA/NSAIDs hypersensitivity, 
although many studies have demonstrated increased levels of 
leukotriene C4 (LTC4) in serum and bronchial and nasal secre-
tions, as well as LTE4 and 15-HETE in urine, after aspirin chal-
lenge in hypersensitive patients. LTC4, which is a mainstay of 
ASA/NSAID-induced hypersensitivity, is produced by LTC4 
synthase, which is distributed mainly in mast cells and baso-
phils. These cells contain many glycogen granules filled with 
various chemical mediators, including histamine, and are de-
granulated by direct or indirect stimulation, with subsequent 
induction of immediate-type hypersensitivity reactions.
24
There are several confounding factors derived from the het-
erogeneous study and control subjects in the present study. 
Further investigations with a larger sample size, particularly in-
cluding subjects with hypersensitivity reactions of the respira-
tory system, and studies aiming to establish the relationship be-
tween FAST results and ethnic groups are needed to confirm 
our results.
The sensitivity of FAST must be improved before it can be ap-
plied for the clinical evaluation of drug sensitivity reactions. For 
example, additional studies have been explored the use of a 
combination of anaphylatoxin
12 and simultaneous measure-
ment of CD63 and CD203
26-29 or CRTH2/DP2.
30 With improved 
sensitivity, FAST may provide a safe, convenient, and rapid 
method for the diagnosis of hypersensitivity to ASA/NSAIDs.
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